Cost-benefit of chickenpox vaccine. Systematic review;Coste-beneficio de la vacuna de la varicela. Revisión sistemática

Anales de Pediatria

Volumn 59, Issue SUPPL. 1, 2003, Pages 54-57

  Diez Domingo J ^a  

^a Centro de Salud Nazaret   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE;

CHICKENPOX; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; REVIEW; TREATMENT OUTCOME; VACCINATION;

EID: 6344234847     PISSN: 16954033     EISSN: None     Source Type: Journal    
DOI: 10.1157/13048802     Document Type: Review

References (17)

1. Birch S, Gafni A. Cost effectiveness/utility analysis: do current decision rules lead us to where we want to be? J Health Economics 1992;11:279-96.
2. Birch S, Gafni A. Economics and the evaluation of vaccination programs: the importance of context. Vaccines Children & Practice. Vaccines Children and Practice 2002;5:38-42.
3. Gafni A, Birch S, Mehrez A. Economics, health and health economics: HYEs versus QALYs. J Health Economics 1993;12:325-39.
4. Birch S, Gafni A. Ethical dimensions of health technology assessment: Being economic with economic principles? Int J Tech Manag 1995;60-72.
5. Lieu T, Cochi SL, Black S. Cost effectiveness of a routine varicella vaccination program for US children. JAMA 1994;271:375-81.
6. Beutels P, Clara R, Tormans G, Van Doorslaer E, Van Damme P. Costs and benefits of routine varicella vaccination in German Children. J Infect Dis 1996;174 (Suppl 3):S335-41.
7. Preblud SR, Orenstein WA, Koplan JP. A benefit-cost analysis of a childhood varicella vaccination programme. Postgrad Med J 1985;61 (Suppl 4):17-22.
8. Huse DM, Meissner HC, Lacey MJ, Oster G. Childhood vaccination against chickenpox: An analysis of benefits and costs. J Pediatr 1994;124:869-74.
9. Coudevielle L, Paree F, Lebrun T, Sailly JC. The value of varicella vaccination in Healthy children: cost-benefit analysis of the situation in France. Vaccine 1999;17:142-51.
10. Díez-Domingo J, Ridao M, Latour J, Ballester A, Morant A. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine 1999;17:1306-11.
11. Schuffham P, Devlin N, Eberhart-Phillips J, Wilson Salt R. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunization schedule. Soc Sci Med 1999;49:763-79.
12. Schuffham PA, Lowin AV, Burges MA. The cost effectiveness of varicella vaccine programs for Australia. Vaccine 2000;18:407-15.
13. Wutzler P, Neiss A, Banz K, Goertz A, Bisanz H. Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunization in Germany. Med Microbiol Immunol 2002;191:89-96.
14. Brisson M, Edmunds WJ. The cost effectiveness of varicella vaccination in Canada. Vaccine 2002;20:1113-25.
15. Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001;127:305-14.
16. Halloran ME, Cochi SL, Lieu TA, Warton M, Ferhrs L. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United states. Am J Epidemiol 1994;140:81-104.
17. Díez-Domingo J, Arístegui J, Calbo Torrecillas F, González Hachero J, Moraga Llop F, Peña Guitian J, et al. Epidemiología y coste de la varicela en niños atendidos en centros de salud de España. Vacunas Invest Pract 2001;2(Supl 1):12-5.